JAZZ

Roche Gets FDA Approval For First Companion Diagnostic For HER2 Treatment In Biliary Tract Cancer

(RTTNews) - Roche (RHHBY) announced that the U.S. Food and Drug Administration has approved an expansion of the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test label to include biliary tract cancer (BTC). This test is now the first and only FDA-approved companion diagnostic to assess HER2-positive status and identify BTC patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii).

HER2 is a receptor protein expressed in a variety of cancers and serves as a predictive biomarker to help determine if a patient will respond to HER2-targeted therapy. No approved and validated HER2 test existed to identify eligible BTC patients until the approval of this expanded label for the PATHWAY HER2 (4B5) test.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.